TY - JOUR
T1 - Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples
AU - Frederick, Mitchell J.
AU - VanMeter, Amy J.
AU - Gadhikar, Mayur A.
AU - Henderson, Ying C.
AU - Yao, Hui
AU - Pickering, Curtis C.
AU - Williams, Michelle D.
AU - El-Naggar, Adel K.
AU - Sandulache, Vlad
AU - Tarco, Emily
AU - Myers, Jeffrey N.
AU - Clayman, Gary L.
AU - Liotta, Lance A.
AU - Petricoin, Emanuel F.
AU - Calvert, Valerie S.
AU - Fodale, Valentina
AU - Wang, Jing
AU - Weber, Randal S.
N1 - Funding Information:
Supported by the Thyroid, Head, and Neck Cancer Foundation Junior Investigator Award (M.J.F.); the University of Texas M.D. Anderson Cancer Center PANTHEON Program (J.N.M.); the NIH Specialized Program of Research Excellence (grant P50CA097007 to J.N.M.); the Ballantyne Distinguished Chair Fund (G.L.C.); various Head and Neck Departmental Research donor funds from patients and the community (R.S.W.); and NIH Cancer Center Support grant CA016672 .
PY - 2011/2
Y1 - 2011/2
N2 - Molecular targeted therapy represents a promising new strategy for treating cancers because many small-molecule inhibitors targeting protein kinases have recently become available. Reverse-phase protein micro-arrays (RPPAs) are a useful platform for identifying dysregulated signaling pathways in tumors and can provide insight into patient-specific differences. In the present study, RPPAs were used to examine 60 protein end points (predominantly phosphoproteins) in matched tumor and nonmalignant biopsy specimens from 23 patients with head and neck squamous cell carcinoma to characterize the cancer phosphoproteome. RPPA identified 18 of 60 analytes globally elevated in tumors versus healthy tissue and 17 of 60 analytes that were decreased. The most significantly elevated analytes in tumor were checkpoint kinase (Chk) 1 serine 345 (S345), Chk 2 S33/35, eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) S65, protein kinase C (PKC) ζ/ι threonine 410/412 (T410/T412), LKB1 S334, inhibitor of kappaB alpha (IκB-α) S32, eukaryotic translation initiation factor 4E (eIF4E) S209, Smad2 S465/67, insulin receptor substrate 1 (IRS-1) S612, mitogen-activated ERK kinase 1/2 (MEK1/2) S217/221, and total PKC ι. To our knowledge, this is the first report of elevated PKC ι in head and neck squamous cell carcinoma that may have significance because PKC ι is an oncogene in several other tumor types, including lung cancer. The feasibility of using RPPA for developing theranostic tests to guide personalized therapy is discussed in the context of these data.
AB - Molecular targeted therapy represents a promising new strategy for treating cancers because many small-molecule inhibitors targeting protein kinases have recently become available. Reverse-phase protein micro-arrays (RPPAs) are a useful platform for identifying dysregulated signaling pathways in tumors and can provide insight into patient-specific differences. In the present study, RPPAs were used to examine 60 protein end points (predominantly phosphoproteins) in matched tumor and nonmalignant biopsy specimens from 23 patients with head and neck squamous cell carcinoma to characterize the cancer phosphoproteome. RPPA identified 18 of 60 analytes globally elevated in tumors versus healthy tissue and 17 of 60 analytes that were decreased. The most significantly elevated analytes in tumor were checkpoint kinase (Chk) 1 serine 345 (S345), Chk 2 S33/35, eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) S65, protein kinase C (PKC) ζ/ι threonine 410/412 (T410/T412), LKB1 S334, inhibitor of kappaB alpha (IκB-α) S32, eukaryotic translation initiation factor 4E (eIF4E) S209, Smad2 S465/67, insulin receptor substrate 1 (IRS-1) S612, mitogen-activated ERK kinase 1/2 (MEK1/2) S217/221, and total PKC ι. To our knowledge, this is the first report of elevated PKC ι in head and neck squamous cell carcinoma that may have significance because PKC ι is an oncogene in several other tumor types, including lung cancer. The feasibility of using RPPA for developing theranostic tests to guide personalized therapy is discussed in the context of these data.
UR - http://www.scopus.com/inward/record.url?scp=79951838654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951838654&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2010.10.044
DO - 10.1016/j.ajpath.2010.10.044
M3 - Article
C2 - 21281788
AN - SCOPUS:79951838654
SN - 0002-9440
VL - 178
SP - 548
EP - 571
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 2
ER -